Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 8/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.64 |
| ▸ | TNFRSF1A | P19438 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | SNCA | P37840 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16181212 | 0.91 | ABCG2 (0.59) | ABCG2ABCB1TNFRSF1AMEN1KMT2A | |
| SCHEMBL30307308 | 0.84 | TNFRSF1A (0.78) | ABCG2ABCB1TNFRSF1AMEN1KMT2A | |
| SCHEMBL16211002 | 0.84 | TNFRSF1A (0.78) | ABCG2ABCB1TNFRSF1AMEN1KMT2A | |
| SCHEMBL16211003 | 0.84 | TNFRSF1A (0.78) | ABCG2ABCB1TNFRSF1AMEN1KMT2A | |
| SCHEMBL12682383 | 0.83 | KDM1A (0.51) | ABCG2ABCB1TNFRSF1AMEN1KMT2A | |
| SCHEMBL19468567 | 0.80 | ABCG2 (0.86) | ABCG2ABCB1TNFRSF1ALMNAMAPT | |
| SCHEMBL30928257 | 0.80 | NFE2L2 (0.71) | ABCG2TNFRSF1AMEN1KMT2AMAPT | |
| SCHEMBL2458577 | 0.79 | ABCG2 (1.00) | ABCG2ABCB1TNFRSF1AMEN1KMT2A | |
| SCHEMBL2458579 | 0.79 | ABCG2 (1.00) | ABCG2ABCB1TNFRSF1AMEN1KMT2A | |
| SCHEMBL25302141 | 0.79 | ABCG2 (0.74) | ABCG2ABCB1TNFRSF1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022174-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTAMED INC (US) | 2017-01-26 | — | — | US | disclosed |
| US-9334251-B2 | Compounds for the treatment of neurodegenerative diseases | PROTAMED, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150274681-A1 | Compounds for the treatment of Neurodegenerative Diseases | PROTEOTECH INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-9085549-B2 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150011604-A1 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8865754-B2 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC. (US) | 2014-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274681-A1 | Compounds for the treatment of Neurodegenerative Diseases | PSEN1, PSEN2, GRN | ABCG2 3674/4885ABCB1 2428/4885TNFRSF1A 4834/4885 |
| US-20150011604-A1 | Compounds for the treatment of neurodegenerative diseases | SNCA, MAPT, PARK7 | ABCG2 1711/4885ABCB1 902/4885TNFRSF1A 4817/4885 |
| US-20170022174-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PSEN1, PSEN2, GRN | ABCG2 3674/4885ABCB1 2428/4885TNFRSF1A 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.